title: Is there a need for PGxceptionalism?
authors.affiliation: Office of Public Health Genomics, Centers for Disease Control and Prevention,1600 Clifton Road, Atlanta, GA 30333, USA. muk1@cdc.gov
authors.forename: Muin J
authors.initials: MJ
authors.lastname: Khoury
authors.forename: Marta
authors.initials: M
authors.lastname: Gwinn
authors.forename: W David
authors.initials: WD
authors.lastname: Dotson
authors.forename: M Scott
authors.initials: MS
authors.lastname: Bowen
mesh_terms: D003362:Cost-Benefit Analysis; D004358:Drug Therapy / Q000191:economics; D064420:Drug-Related Side Effects and Adverse Reactions; D019317:Evidence-Based Medicine; D006801:Humans; D010597:Pharmacogenetics / Q000191:economics / Q000592:standards*